| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
47,830,000 |
| Market
Cap: |
12.96(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.2565 - $3.49 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a main role. Co. is developing uproleselan, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia, a hematologic cancer, and potentially other hematologic cancers. Co. is also developing a drug candidate, GMI-1359, that simultaneously targets both E-selectin and a chemokine receptor known as CXCR4. Co. has designed an antagonist of E-selectin, GMI-1687, that could be suitable for subcutaneous administration.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
65,403 |
2,581,565 |
| Total Buy Value |
$0 |
$0 |
$90,256 |
$4,837,462 |
| Total People Bought |
0 |
0 |
1 |
9 |
| Total Buy Transactions |
0 |
0 |
2 |
21 |
| Total Shares Sold |
0 |
0 |
0 |
4,053,849 |
| Total Sell Value |
$0 |
$0 |
$0 |
$12,677,616 |
| Total People Sold |
0 |
0 |
0 |
2 |
| Total Sell Transactions |
0 |
0 |
0 |
6 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Barris Peter J |
10% Owner |
– – • |
2014-01-15 |
4 |
B |
$8.00 |
$8,000,000 |
I/I |
1,000,000 |
4,093,377 |
1.5 |
- |
|
| Barris Peter J |
10% Owner |
– – • |
2014-01-15 |
4 |
A |
$0.00 |
$0 |
I/I |
6,988,160 |
3,580,877 |
|
- |
|
| Nea Partners 10 L P |
10% Owner |
– – • |
2014-01-15 |
4 |
B |
$8.00 |
$3,900,000 |
D/D |
487,500 |
4,481,758 |
2.45 |
- |
|
| Nea Partners 10 L P |
10% Owner |
– – • |
2014-01-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,407,283 |
3,994,258 |
|
- |
|
| Gust William M. |
Director |
– • – |
2014-01-15 |
4 |
A |
$0.00 |
$0 |
I/I |
339,686 |
409,947 |
|
- |
|
| Thackray Helen M. |
VP Clinical Development, CMOOf |
• – – |
2014-01-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
184,615 |
|
- |
|
| Top Franklin H Jr |
Director |
– • – |
2014-01-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
605 |
|
- |
|
| Barrett M James |
Director |
– • • |
2014-01-09 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
586,975 |
|
- |
|
| King Rachel K. |
President, CEOOfficer |
• • – |
2014-01-09 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
159,096 |
|
- |
|
| King Rachel K. |
President, CEOOfficer |
• • – |
2014-01-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
8,706 |
|
- |
|
| Magnani John L. |
VP of Research, CSOOfficer |
• • – |
2014-01-09 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,845 |
|
- |
|
| Magnani John L. |
VP of Research, CSOOfficer |
• • – |
2014-01-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
80,405 |
|
- |
|
| Baldwin John J. |
Director |
– • – |
2014-01-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
605 |
|
- |
|
| Hahn Brian M. |
CFOOfficer |
• – – |
2014-01-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
9,085 |
|
- |
|
| Gust William M. |
Director |
– • – |
2014-01-09 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
70,261 |
|
- |
|
| Henos Michael A |
Director |
– • – |
2014-01-09 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
126,961 |
|
- |
|
| Sandell Scott D |
10% Owner |
– – • |
2014-01-09 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
586,975 |
|
- |
|
| Nea Partners 10 L P |
10% Owner |
– – • |
2014-01-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
586,975 |
|
- |
|
| Barris Peter J |
10% Owner |
– – • |
2014-01-09 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
586,975 |
|
- |
|
| Sanofi-Aventis |
10% Owner |
– – • |
2013-11-06 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,193,625 |
|
- |
|
145 Records found
|
|
Page 6 of 6 |
|
|
